Navigation Links
Affymetrix 500K array used to identify memory gene

Affymetrix Inc. announced today that researchers at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona have used the Affymetrix 500K Array to discover a gene--called Kibra--associated with memory performance in humans. The team's findings may be used to develop new medicines for memory-based diseases such as Alzheimer's and Parkinson's by providing scientists with a better understanding of how memory works at the molecular level.

The study entitled, "Common KIBRA alleles are associated with human memory performance," will be published in the Oct. 20, 2006 issue of Science. The research team was led by Dietrich Stephan, Ph.D., director of TGen's Neurogenomics Division. It included colleagues at the University of Zurich in Switzerland, Banner Alzheimer's Institute and Mayo Clinic Scottsdale.

"Using the latest Affymetrix 500K Array, we have shed light on the fundamental biological process of human memory performance," said Dr. Stephan. "We can use this new understanding to develop drugs that will improve memory function."

Until now, researchers did not have access to the high-density technology needed to examine the genetic components associated with memory performance. The team at TGen used Affymetrix Human Mapping 500K Arrays to analyze 500,000 DNA markers simultaneously, providing a genetic blueprint for the memory-study participants. The researchers discovered the Kibra gene by comparing the genetic blueprints of people with good memory vs. poor memory and looking for the genetic variations consistently present in one group, but not the other. They then validated their discovery by replicating the Kibra gene finding in two separate and distinct groups of subjects.

"This memory study is a perfect example of how the use of advanced technologies in human genetics yields fundamental discoveries," said Stephen P.A. Fodor, Ph.D., chairman and CEO at Affymetrix.

To learn more about this breakthrough:


'"/>

Source:Affymetrix, Inc.


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
6. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
7. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
8. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
9. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
10. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
11. Breakthrough Microarray-based Technology for the Study of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology: